| Ytd | 81.95% | |
| 1y | 223.56% |
| Open | 14.38 | Prev Close | 14.47 | Low | 14.23 | High | 14.57 | Mkt Cap | 1.22B |
| Vol | 59.67K | Avg Vol | 1.55M | EPS | -0.52 | P/E | -27.83 | Forward P/E | -16.55 |
| Beta | 0.82 | Short Ratio | 13.43 | Inst. Own | 85.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 13.39 | 200-d Avg | 12.71 | 1yr Est | 33.33 |
CRVS News
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) were up 5.1% during mid-day
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announ
SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:
Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to inc
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive dat
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soqu
Stocks traded higher with Dow Jones up by 1,000 points. Consumer discretionary shares rose while ene
The Dow Jones index rose 700 points, Autoliv Inc (NYSE: ALV) reported strong results causing a jump
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) have been given a consensus
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price fell 6.5% during trading
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference ca
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just o
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Companies Reporting Before The Bell • Mastercard Inc. (NYSE:MA) is expected to report quarterly ear
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018